Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management

Shivanshan Pathmanathan; Arsalan Tariq; Adam Pearce; Handoo Rhee; Samuel Kyle; Sheliyan Raveenthiran; David Wong; Rhiannon McBean; Phillip Marsh; Steven Goodman; Nattakorn Dhiantravan; Rachel Esler; Nigel Dunglison; Anojan Navaratnam; John Yaxley; Paul Thomas; David A Pattison; Jeffrey C Goh; Chun Loo Gan; Matthew J Roberts

doi:10.1007/s00259-023-06380-4

Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management

Eur J Nucl Med Mol Imaging. 2023 Dec;51(1):295-303. doi: 10.1007/s00259-023-06380-4. Epub 2023 Aug 18.

Authors

Shivanshan Pathmanathan¹, Arsalan Tariq^{2

3}, Adam Pearce^{2

3

4}, Handoo Rhee^{3

5}, Samuel Kyle^{6

7}, Sheliyan Raveenthiran^{2

8}, David Wong⁹, Rhiannon McBean⁹, Phillip Marsh¹⁰, Steven Goodman⁷, Nattakorn Dhiantravan⁷, Rachel Esler^{2

4}, Nigel Dunglison^{2

3}, Anojan Navaratnam^{2

3}, John Yaxley^{2

3

4}, Paul Thomas^{3

7}, David A Pattison^{3

7}, Jeffrey C Goh^{1

3}, Chun Loo Gan¹, Matthew J Roberts^{11

12

13

14}

Affiliations

¹ Department of Medical Oncology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
² Department of Urology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, 4029, Australia.
³ Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
⁴ Wesley Urology Clinic, The Wesley Hospital, Brisbane, Queensland, Australia.
⁵ Department of Urology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
⁶ Department of, Medical Imaging, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
⁷ Department of Nuclear Medicine, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
⁸ Department of Urology, Redcliffe Hospital, Brisbane, Queensland, Australia.
⁹ I-MED Radiology, The Wesley Hospital, Brisbane, Queensland, Australia.
¹⁰ Department of Diagnostic Radiology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
¹¹ Department of Urology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, 4029, Australia. [email protected].
¹² Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia. [email protected].
¹³ Department of Urology, Redcliffe Hospital, Brisbane, Queensland, Australia. [email protected].
¹⁴ Centre for Clinical Research, The University of Queensland, Brisbane, QLD, Australia. [email protected].

Abstract

Purpose: There is an emerging role of the use of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in renal cell carcinoma. Herein, we report our experience in use of PSMA PET in recurrent or metastatic renal cell carcinoma (RCC).

Methods: A retrospective analysis of all patients who underwent PSMA PET for suspected recurrent or de-novo metastatic RCC between 2015 and 2020 at three institutions was performed. The primary outcome was change in management (intensification or de-intensification) following PSMA PET scan. Secondary outcomes included histopathological correlation of PSMA avid sites, comparison of sites of disease on PSMA PET to diagnostic CT and time to systemic treatment.

Keywords: Management; Positron emission tomography; Prostate specific membrane antigen; Renal cell carcinoma; Staging.

MeSH terms

Carcinoma, Renal Cell* / diagnostic imaging
Carcinoma, Renal Cell* / pathology
Carcinoma, Renal Cell* / therapy
Gallium Radioisotopes
Humans
Kidney Neoplasms* / diagnostic imaging
Kidney Neoplasms* / pathology
Kidney Neoplasms* / therapy
Male
Positron Emission Tomography Computed Tomography / methods
Positron-Emission Tomography
Prostate / pathology
Prostate-Specific Antigen / metabolism
Prostatic Neoplasms* / diagnostic imaging
Prostatic Neoplasms* / pathology
Prostatic Neoplasms* / therapy
Retrospective Studies

Substances

Prostate-Specific Antigen
Gallium Radioisotopes